Jazz Pharmaceuticals PLC $JAZZ Shares Sold by Distillate Capital Partners LLC

Distillate Capital Partners LLC lowered its position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 13.5% in the second quarter, according to the company in its most recent filing with the SEC. The firm owned 107,811 shares of the specialty pharmaceutical company’s stock after selling 16,774 shares during the quarter. Distillate Capital Partners LLC owned about 0.18% of Jazz Pharmaceuticals worth $11,441,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the company. Claret Asset Management Corp raised its stake in shares of Jazz Pharmaceuticals by 23.8% in the second quarter. Claret Asset Management Corp now owns 2,175 shares of the specialty pharmaceutical company’s stock worth $231,000 after purchasing an additional 418 shares during the last quarter. Schroder Investment Management Group increased its holdings in Jazz Pharmaceuticals by 90.1% in the 2nd quarter. Schroder Investment Management Group now owns 17,816 shares of the specialty pharmaceutical company’s stock worth $1,891,000 after buying an additional 8,444 shares during the period. Mackenzie Financial Corp increased its holdings in Jazz Pharmaceuticals by 997.1% in the 2nd quarter. Mackenzie Financial Corp now owns 208,409 shares of the specialty pharmaceutical company’s stock worth $22,116,000 after buying an additional 189,412 shares during the period. Measured Wealth Private Client Group LLC raised its position in Jazz Pharmaceuticals by 47.1% during the 2nd quarter. Measured Wealth Private Client Group LLC now owns 4,855 shares of the specialty pharmaceutical company’s stock worth $515,000 after buying an additional 1,554 shares during the last quarter. Finally, Level Four Advisory Services LLC acquired a new stake in Jazz Pharmaceuticals during the 2nd quarter valued at approximately $367,000. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Insider Buying and Selling

In related news, Director Bruce C. Cozadd sold 77,500 shares of Jazz Pharmaceuticals stock in a transaction on Wednesday, November 26th. The shares were sold at an average price of $177.81, for a total value of $13,780,275.00. Following the sale, the director owned 393,332 shares of the company’s stock, valued at approximately $69,938,362.92. This trade represents a 16.46% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Heather Ann Mcsharry sold 3,415 shares of the business’s stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $177.78, for a total transaction of $607,118.70. Following the completion of the sale, the director directly owned 20,449 shares of the company’s stock, valued at approximately $3,635,423.22. The trade was a 14.31% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 122,393 shares of company stock valued at $21,568,254 in the last 90 days. Corporate insiders own 4.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on JAZZ shares. The Goldman Sachs Group upped their price objective on shares of Jazz Pharmaceuticals from $162.00 to $185.00 and gave the company a “buy” rating in a report on Friday, August 29th. Weiss Ratings restated a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a research report on Wednesday, November 26th. Robert W. Baird increased their price target on Jazz Pharmaceuticals from $160.00 to $209.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 18th. Bank of America lifted their price objective on Jazz Pharmaceuticals from $230.00 to $247.00 and gave the company a “buy” rating in a research note on Tuesday, November 18th. Finally, UBS Group restated a “neutral” rating and issued a $188.00 target price (up previously from $163.00) on shares of Jazz Pharmaceuticals in a research note on Monday, November 24th. Thirteen investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $195.67.

Jazz Pharmaceuticals Price Performance

NASDAQ:JAZZ opened at $172.12 on Tuesday. The company has a quick ratio of 1.37, a current ratio of 1.62 and a debt-to-equity ratio of 1.17. Jazz Pharmaceuticals PLC has a 52 week low of $95.49 and a 52 week high of $182.99. The stock’s 50-day moving average price is $144.71 and its 200-day moving average price is $125.74. The stock has a market capitalization of $10.46 billion, a PE ratio of -25.57, a price-to-earnings-growth ratio of 8.49 and a beta of 0.29.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.